2-APQC,a small-molecule activator of Sirtuin-3(SIRT3),alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis

扫码查看

原文链接

NETL
NSTL
万方数据

外文摘要：Sirtuin 3(SIRT3)is well known as a conserved nicotinamide adenine dinucleotide+(NAD+)-dependent deacetylase located in the mitochondria that may regulate oxidative stress,catabolism and ATP production.Accumulating evidence has recently revealed that SIRT3 plays its critical roles in cardiac fibrosis,myocardial fibrosis and even heart failure(HF),through its deacetylation modifications.Accordingly,discovery of SIRT3 activators and elucidating their underlying mechanisms of HF should be urgently needed.Herein,we identified a new small-molecule activator of SIRT3(named 2-APQC)by the structure-based drug designing strategy.2-APQC was shown to alleviate isoproterenol(ISO)-induced cardiac hypertrophy and myocardial fibrosis in vitro and in vivo rat models.Importantly,in SIRT3 knockout mice,2-APQC could not relieve HF,suggesting that 2-APQC is dependent on SIRT3 for its protective role.Mechanically,2-APQC was found to inhibit the mammalian target of rapamycin(mTOR)-p70 ribosomal protein S6 kinase(p70S6K),c-Jun N-terminal kinase(JNK)and transforming growth factor-β(TGF-β)/small mother against decapentaplegic 3(Smad3)pathways to improve ISO-induced cardiac hypertrophy and myocardial fibrosis.Based upon RNA-seq analyses,we demonstrated that SIRT3-pyrroline-5-carboxylate reductase 1(PYCR1)axis was closely assolated with HF.By activating PYCR1,2-APQC was shown to enhance mitochondrial proline metabolism,inhibited reactive oxygen species(ROS)-p38 mitogen activated protein kinase(p38MAPK)pathway and thereby protecting against ISO-induced mitochondrialoxidative damage.Moreover,activation of SIRT3 by 2-APQC could facilitate AMP-activated protein kinase(AMPK)-Parkln axis to inhibit ISO-induced necrosis.Together,our results demonstrate that 2-APQC is a targeted SIRT3 activator that alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis,which may provide a new clue on exploiting a promising drug candidate for the future HF therapeutics.

作者：

Fu Peng、Minru Liao、Wenke Jin、Wei Liu、Zixiang Li、Zhichao Fan、Ling Zou、Siwei Chen、Lingjuan Zhu、Qian Zhao、Gu Zhan、Liang Ouyang、Cheng Peng、Bo Han、Jin Zhang、Leilei Fu

展开 >

作者单位：

West China School of Pharmacy and Department of Biotherapy,Cancer Center and State Key Laboratory of Biotherapy,West China Hospital,Sichuan University,Chengdu 610041,China

Sichuan Engineering Research Center for Biomimetic Synthesis of Natural Drugs,School of Life Science and Engineering,Southwest Jiaotong University,Chengdu 610031,China

State Key Laboratory of Southwestern Chinese Medicine Resources,Hospital of Chengdu University of Traditional Chinese Medicine,School of Pharmacy,Chengdu University of Traditional Chinese Medicine,Chengdu 611137,China

School of Pharmaceutical Sciences,Health Science Center,Shenzhen University,Shenzhen 518060,China

School of Traditional Chinese Materia Medica,Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education,Shenyang Pharmaceutical University,Shenyang 110016,China

展开 >

基金：

National Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaNational Natural Science Foundation of ChinaShenzhen science and technology research and development fundsInnovation Team and Talents Cultivation Program of National Administration of Traditional Chinese MedicineNatural Science Foundation of Liaoning Province

项目编号：

82173666823740208207399822107015JCYJ20210324094612035ZYYCXTD-D-2022092022-MS-251

出版年：

2024

DOI：

10.1038/s41392-024-01816-1

信号转导与靶向治疗(英文)

CSTPCD

ISSN：

年,卷(期)：2024.9(6)